

Selected Pharmaceuticals in Development as of January 24, 2023



Cardiovascular and Metabolism

aprocitentan

Difficult to treat hypertension

Milvexian (Factor Xla)

Prevention and Treatment of Thrombosis

JNJ-0237

Autosomal Dominant Polycystic Kidney Disease

AAV-RPGR

Retinitis Pigmentosa

JNJ-7100

Diabetic Macular Oedema

JNJ-1887

Macular Degeneration

AAV-CNGB3

Achromatopsia

AAV-CNGA3

Achromatopsia

JNJ-0795

Non-Alcoholic Steatohepatitis



CABENUVA

HIV Adolescents

VAC18193

RSV Adult Vaccine

VAC52416

Multivalent ExPEC Vaccine

JNJ-3989 Combination Therapy

Hepatitis B

JNJ-7744

Hepatitis B

VAC52150

Monovalent Ebola Virus Vaccine

REMICADE (Infliximab)

COVID-19

JNJ-0953

Influenza

JNJ-1802

Dengue Prophylaxis

JNJ-3283 Combination Therapy

Hepatitis B

VAC31518

Janssen COVID-19 Vaccine

VAC89220

HIV Px Vaccine

JNJ-3989

Hepatitis B/D Co-infection

Ultra Long-Acting

HIV



STELARA (ustekinumab)
Pediatric Juvenile Psoriatic Arthritis

TREMFYA (guselkumab)
Psoriatic Arthritis Structural Damage

TREMFYA (guselkumab)
Crohn's Disease

SIMPONI (golimumab)
Pediatric Ulcerative Colitis

nipocalimab
Idiopathic inflammatory myopathy

nipocalimab
Systemic lupus erythematosus

JNJ-4804 Combination Therapy
Crohn's Disease

JNJ-2113
Psoriasis

TREMFYA (guselkumab)
Subcutaneous Induction (ASTRO)

TREMFYA (guselkumab)
Ulcerative Colitis Monotherapy

STELARA (ustekinumab)
Pediatric Ulcerative Colitis

nipocalimab
Warm Autoimmune Hemolytic Anemia

nipocalimab
Hemolytic disease of the fetus and newborn

nipocalimab
Rheumatoid Arthritis

JNJ-4804 Combination Therapy
Psoriatic Arthritis

JNJ-1459
Psoriasis

TREMFYA (guselkumab)
Crohn's Disease Subcutaneous Induction

TREMFYA (guselkumab)
Pediatric Psoriasis

STELARA (ustekinumab)
Pediatric Crohn's Disease

TREMFYA (guselkumab)
Giant Cell Arteritis

nipocalimab
Sjogren's Syndrome

bermekimab
Hidradenitis Suppurativa

JNJ-4804 Combination Therapy
Ulcerative Colitis

JNJ-9280
Inflammatory Bowel Disease



JNJ-4703

Rheumatoid Arthritis

seltorexant

Adjunctive treatment for major depressive disorder with insomnia symptoms

aticaprant

Adjunctive Major Depressive Disorder

SPRAVATO (esketamine)

Major Depressive Disorder with Suicidal Ideation
Pediatrics

JNJ-1813

Epilepsy

JNJ-0376

Parkinson's Disease

nipocalimab

Chronic Inflammatory Demyelinating Polyneuropathy

seltorexant

Probable Alzheimer's with clinically significant agitation/aggression

anti-phospho-tau mAb

Alzheimer's Disease

VAC20121 *

Alzheimer's Disease

nipocalimab

Generalized Myasthenia Gravis

nipocalimab

Generalized Myasthenia Gravis Pediatrics

P2X7 antagonist

Bipolar Disease

small molecule MGLLi

Psychiatric Disorders



niraparib

L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone

BALVERSA (erdafitinib)

Urothelial cancer

teclistamab (BCMA/CD3)

Relapsed Refractory multiple myeloma

IMBRUVICA Ibrutinib

Relapsed Refractory Mantle Cell Lymphoma (VEGA)

TAR-200 (RIS/gemcitabine plus cetrelimab)

Muscle invasive bladder cancer

DARZALEX (daratumumab)

Smoldering multiple myeloma (SMM3001)

CARVYKTI (Ciltacabtagene autoleucel)

Frontline Multiple Myeloma TNI

teclistamab

TE NDMM maintenance (MajesTEC-4)

IMBRUVICA (ibrutinib)

Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)

ERLEADA (apalutamide)

Tablet Reduction

niraparib / abiraterone acetate

M1 Metastatic Castration-Sensitive Prostate Cancer in combination with abiraterone acetate and Prednisone

IMBRUVICA (ibrutinib)

Relapsed Refractory patients with Mantle Cell Lymphoma in combination with venetoclax (SYMPATICO)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant eligible (PERSEUS)

ERLEADA (apalutamide)

High risk prostate cancer (PROTEUS)

CARVYKTI (Ciltacabtagene autoleucel)

Relapsed Refractory multiple myeloma w/1-3 PL

teclistamab (BCMA/CD3)

Multiple Myeloma 1-3PLs

IMBRUVICA (ibrutinib)

Treatment naïve patients with Mantle Cell Lymphoma in combination with Bendamustine and Rituximab (SHINE)

talquetamab (GPRC5D/CD3)

Relapsed Refractory Multiple Myeloma

amivantamab / lazertinib

Non Small Cell Lung Cancer

IMBRUVICA (ibrutinib)

Relapsed Refractory patients with Indolant Non-Hodgkins Lymphoma (SELENE)

DARZALEX (daratumumab)

Frontline multiple myeloma transplant ineligible (CEPHEUS)

ERLEADA (apalutamide)

Localized prostate cancer

talquetamab (GPRC5D/CD3)

Relapsed Refractory Multiple Myeloma A-CD38 Naïve (MonumenTAL-3)

RYBREVANT (amivantamab)

Subcutaneous (PALOMA-3)

amivantamab / lazertinib

Non Small Cell Lung Cancer 2L

BALVERSA (erdafitinib)

Non muscle invasive bladder cancer

VAC85135

Hematological Malignancies

JNJ-8114

Prostate Cancer

JNJ-6617

Hematological Malignancies

JNJ-6633

Hematological Malignancies

RYBREVATM (amivantamab)

Frontline Non Small Cell Lung Cancer in combination with chemotherapy

BALVERSA (erdafitinib)

Tumor Agnostic

erdafitinib

Intravesical Delivery System for Localized Bladder Cancer

JNJ-5322

Multiple Myeloma

JNJ-9414

Prostate Cancer

JNJ-4681

Hematological Malignancies

TAR-200 (RIS/gemcitabine plus cetrelimab)

Non muscle invasive bladder cancer

JNJ-8343

Prostate Cancer

JNJ-8543

Hematological Malignancies

JNJ-8780

Hematological Malignancies

JNJ-6420

Prostate Cancer

JNJ-1330

Colorectal Cancer

Pulmonary Hypertension

UPTRAVI (selexipag)

Pediatric pulmonary arterial hypertension

OPSUMIT (macitentan)

Pediatric pulmonary arterial hypertension

macitentan

Pulmonary arterial hypertension 75mg

macitentan w/tadalafil FDC

Pulmonary arterial hypertension

macitentan

Chronic thromboembolic pulmonary hypertension 75mg

prostacyclin receptor agonist

Pulmonary Arterial Hypertension

This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. *AC Immune ACI-35.030. Strategic Partnerships, Collaborations, and Licensing arrangements - XARELTO: Bayer; milvexian: Bristol Myers Squibb; apocitentan: Idorsia; X-Linked Retinitis Pigmentosa (AAV-RPGR) and Achromatopsia Gene Therapies (CNGA3 and CNGB3): MeiraGTx; JNJ-7100: Exonate; JNJ-1887: Hemera Biosciences; PNPLA3: Arrowhead Pharmaceuticals; COMPLERA / EVIPLERA, ODEFSEY, SYMTUZA, PREZCOBIX / REZOLSTA FDC: Gilead Sciences; JULUCA and Long acting HIV injectible treatment regimen of rilpivirine and cabotegravir: ViiV Healthcare; COVID-19 vaccine: funded in part with federal funds from the U.S. Department of Health and Human Services; JNJ-3989: Arrowhead Pharmaceuticals; bacteriophage products using recombinant CRISPR/Cas3 Phage platform: Locus Biosciences; Cloudbreak antiviral conjugates (AVCs) including CD388: Cidara Therapeutics; Janssen's HIV vaccine program: IPCAVD, MHRP, HJF, the Ragon Institute, IAVI, Bill & Melinda Gates Foundation, NIAID, U.S. Military HIV Research Program, U.S. Army Medical Materiel Development Activity, MIT, Harvard, HVTN, SAMRC, Bavarian Nordic; Zika vaccine: Beth Israel Deaconess Medical Center (Harvard Medical School); ExPEC: GSK; REMICADE and SIMPONI/SIMPONI ARIA: Schering-Plough (Ireland) Company, a subsidiary of Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation; TREMFYA: MorphoSys AG; JNJ-2113, JNJ-4238 and JNJ-5186: Protagonist Therapeutics; Tau Vaccine: AC Immune SA; JNJ-1813: Addex Pharmaceuticals; IMBRUVICA: Pharmacyclics, LLC, an AbbVie company; ZYTIGA: BTG International; VELCADE: Millennium, The Takeda Oncology Company; DARZALEX and DARZALEX FASPRO: Genmab A/S; BALVERSA: Astex Pharmaceuticals; ERLEADA: Regents of California and Memorial Sloan Kettering; cilta-cel: Legend Biotech; niraparib: TESARO, an oncology-focused business within GSK; lazertinib: Yuhan Corporation; Duobody Platform bispecific antibody programs: Genmab A/S; ENHANZE platform; Halozyme Therapeutics; XmAb CD28 bispecific antibodies; Xencor; iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates: Fate Therapeutics; UPTRAVI and OPSUMIT: Nippon Shinyaku (co-promotion in Japan); Janssen's Monovalent Ebola Vaccine: Bavarian Nordic A/S, NIAID, IMI2, EFPIA, BARDA, NIH; Filovirus multivalent vaccine: Bavarian Nordic

